Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with Multiple Myeloma (MM).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Confirmed diagnosis of multiple myeloma that is relapsed and/or refractory for which no curative option exists.
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
During the dose expansion part of the study patients must have measurable disease defined by at least 1 of the following 2 measurements:
Exclusion criteria
Patients who are currently receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least one week prior to the start of treatment with LGH447:
Other protocol-defined inclusion/exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
79 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal